Day: February 14, 2022

Orphazyme A/SCompany announcementNo. 04/2022  www.orphazyme.comCompany Registration No. 32266355Copenhagen, Denmark, February 14, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the Board of Directors has decided to limit the scope of the proposed authorizations set forward under items 1.2, 1.3 and 1.4 of the agenda of the Extraordinary General Meeting to be held tomorrow, February 15, 2022. This entails that the proposed authorizations to increase the share capital by issuance of shares, convertible bonds and warrants, as applicable, will be subject to such share capital increases taking place at or above market price and that share capital increases below...

BRISBANE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the closing of its public offering of 5,742,026 shares of its Class A common stock at a price to the public of $15.00 per share, which includes the full exercise of the underwriters’ option to purchase up to 748,959 additional shares. The gross proceeds to Vera from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are approximately $86.1 million. All of the shares were sold by Vera. J.P. Morgan, Cowen, and Evercore ISI acted as joint book-running managers for the offering. Registration statements relating to these securities...

BALA CYNWYD, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) regarding the clinical hold on Larimar’s CTI-1601 program. FDA stated it is maintaining its clinical hold at this time and that additional data is needed to resolve the clinical hold. Larimar is further analyzing previously completed studies, and is evaluating if additional studies are warranted. The Company also intends to engage FDA to determine how best to provide these data. Larimar is currently reassessing guidance on the timing of the planned Jive open-label extension and pediatric multiple-ascending dose clinical trials as it...

ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2021 after the market closes on Thursday, February 24, 2022.  MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, February 24, 2022, at 4:30 pm ET. The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the Conference ID# 1067087. The listen-only webcast of the conference call can be accessed under “Events & Presentations”...

BURNABY, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one investor meetings and a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference.Fireside Chat Details:   Date:Time:Presenter: Thursday, February 17, 20225:00-5:30 pm ETIan Mortimer, President and CEO   The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon’s website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. About Xenon Pharmaceuticals Inc. We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics...

TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) — SmartCentres Real Estate Investment Trust (“SmartCentres” or the “Trust”) (TSX: SRU.UN) announced today that it will issue its financial results for the three months and year ending December 31, 2021 on Tuesday, February 15, 2022. SmartCentres will hold a conference call on Wednesday, February 16, 2022 at 11:00 a.m. (ET). Participating on the call will be members of SmartCentres’ senior management. Investors are invited to access the call by dialing 1-855-353-9183 and then keying in the participant passcode 20510#. A recording of this call will be made available Wednesday, February 16, 2022 beginning at 8:30 p.m. (ET) through to 8:30 p.m. (ET) on Wednesday, February 23, 2022. To access the recording, please call 1-855-201-2300, enter the conference access code 20510# and then key in the...

VANCOUVER, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) — Search Minerals Inc. (TSXV: SMY | OTCQB: SHCMF) (“Search” or the “Company”), is pleased to announce that Search will significantly bolster its expertise with the addition of Ken Baxter and W. Andrew Krusen, Jr to its Advisory Committee. We are also pleased to engage Pretium Capital Group for investor public relations and related communication services. ADVISORY COMMITTEE APPOINTMENTS KEN BAXTER Ken Baxter holds a Bachelor of Science Geology and a Master of Scientific Studies, both from the University of Queensland in Australia. Mr. Baxter has over 35 years experience in design and commissioning of process plants including innovative and technically challenging plants. He has successfully managed design teams for gold and base metals, predominantly copper and he was responsible...